InnoMedica Holding AG

About us
InnoMedica is developing a new generation of cancer drugs based on a highly innovative drug delivery system. This can treat cancer significantly more effectively, while for patients the side effects are reduced to a minimum.

In January 2013 InnoMedica initiated the project Targeted Liposomal Doxorubicin TLD-1. The strategy is to develop and commercialize novel therapeutics for the treatment of cancer. This new generation of chemotherapeutic agents is based on existing cytostatic drugs, which are being used in a new galenic form in cancer therapy.

InnoMedica Holding AG is a stock corporation under Swiss law. It was originally founded by specialists in finance and medicine with the aim of offering its shareholders a forward-looking investment opportunity with participation in the development of geriatric medicine.

In a continuing turbulent stock market environment, InnoMedica has increasingly started its own projects for the development of innovative products in medicine in addition to investments in listed companies. By resolution of the AGM on June 28, 2012, this activity was now defined as the core task of the company.